Abstract:Abstract BACKGROUND In the real-world setting, biologic therapy in patients with ulcerative colitis (UC) may require dose escalation if initial response is limited or due to loss of response. Dose escalation leads to higher treatment costs and may cause difficulties obtaining prior authorization and approvals from health plans. This study compared treatment persistence while on labeled maintenance dose among advanced therapy (ADT)-naïve patients with UC on ustekinumab or adalimumab. METHODS Adults with UC initiated on ustekinumab or adalimumab (index date: 10/21/2019 - 03/02/2022) were selected from the IQVIA PharMetrics® Plus database. Patients were ADT-naïve (i.e., no claim for UC-indicated ADT) and had no other autoimmune diseases in the 12-month baseline period before the index date. Cohorts were balanced on baseline characteristics using inverse probability of treatment weights. Persistence while on the labeled maintenance dose was defined as (1) no gaps between days of therapy supply (ustekinumab, >120 days; adalimumab, >60 days), and (2) absence of any dose change from the maintenance dose per US label. Composite endpoints of being persistent while corticosteroid-free (<14 consecutive days of corticosteroid supply after day 90 post-index) and persistent while on monotherapy (no immunomodulators or ADT) were also evaluated. Endpoints were assessed from the maintenance phase start until the earliest of discontinuation (event), corticosteroid use (event), immunomodulator or ADT use (event), dose change (censored), 12 months follow-up, or data end (censored) using weighted Kaplan-Meier and Cox proportional hazards model analyses. RESULTS There were 371 and 1,726 patients in the weighted ustekinumab versus adalimumab cohort, respectively (Fig. 1). At 12 months after the maintenance phase start, 88.6% and 61.7% of the ustekinumab versus adalimumab cohort were persistent while on the labeled maintenance dose; persistence was 4.21 times higher in the ustekinumab cohort (p-value: <0.001; Fig 2a). Further, 70.0% and 43.9% of the ustekinumab versus adalimumab cohorts were persistent and corticosteroid-free while on the labeled maintenance dose; persistence was 2.31 times higher in the ustekinumab cohort (p-value: <0.001; Fig 2b). Finally, 84.4% and 55.1% of the ustekinumab versus adalimumab cohorts were persistent while on monotherapy and on the labeled maintenance dose; persistence was 3.38 times higher in the ustekinumab cohort (p-value: <0.001; Fig 2c). CONCLUSIONS ADT-naïve patients with UC initiated on ustekinumab were significantly more persistent while on the labeled maintenance dose, including persistent while corticosteroid-free and while on monotherapy, compared to patients initiated on adalimumab. Results may help with selecting a biologic for ADT-naive patients with UC. Figure 1 Selected baseline characteristics in weighted ustekinumab and adalimumab cohorts Figure 2 Persistence while on US labelled dose among weighted ustekinumab and adalimumab cohorts: a) persistent on index biologic, b) persistent and corticosteroid-free, c) persistent and on monotherapy

Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors

Treatment Persistence of Interleukin-17 Inhibitor Class Drugs among Patients with Psoriasis in Japan: a Retrospective Database Study.

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors

Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naïve patients-A retrospective register-based cohort study in Finland and Sweden

Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study

Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab

REAL-WORLD TREATMENT PERSISTENCE AMONG ADVANCED THERAPY-EXPERIENCED PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States

Medication persistence of targeted immunomodulators for plaque psoriasis: A retrospective analysis using a U.S. claims database

Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks

A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of pasi score

The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study

Persistence of treatment with biologics for patients with psoriasis: a real‐world analysis of 16 545 biologic‐naïve patients from the French National Health Insurance database (SNIIRAM)

Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease

A Two-Year Real-Life Study

Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry

PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG ADVANCED THERAPY-NAÏVE PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB